UNSPSC 51191563: Quincarbate

This classification denotes a thiazide diuretic with the molecular formula C17H18ClNO6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U40Q9GE876, chemically known as ethyl 10-chloro-3-(ethoxymethyl)-2,3,6,9-tetrahydro-9-oxo-p-dioxino(2,3-g)quinoline-8-carboxylate but generally known as quincarbate, which bears US NIH Compound Identifier 323967. European Medicines Agency schedules Quincarbate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10205MIG.

UNSPSC 51191563 Quincarbate, a Commodity code, covers chemical supply products used in state and local water treatment, facility maintenance, and pharmaceutical distribution operations. Recent solicitations show the code capturing purchase requests for water-treatment chemicals like sodium bisulfite and multi-source generic pharmaceuticals and over-the-counter products distributed through authorized wholesaler networks. The issuing bodies include municipal utilities, state procurement offices administering cooperative purchasing alliances, and state and local government health and social-service facilities. Buyers specify detailed product quality standards, National Drug Codes or equivalent chemical specifications, and delivery schedules aligned with operational demand.

The City of Meriden (Connecticut) posted an IFB on July 8, 2026 for sodium bisulfite chemical supply to support its Water Pollution Control Facility, with bids due July 29, 2026; contractors must carry General Liability coverage of $1,000,000 to $2,000,000 and performance and payment bonds. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP posted January 20, 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products for distribution across Minnesota, Oregon, and participating state and local government facilities; the response deadline was March 26, 2026, and awarded vendors were to be provided to AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC by May 15, 2026, with contracts effective July 1, 2026. Evaluation weighting for the MMCAP solicitation emphasized price competitiveness at 75 percent, with administrative compliance and EDI capability accounting for 15 percent combined. Both opportunities require vendors to maintain comprehensive insurance and comply with manufacturing, regulatory, or safety standards specific to the chemical or pharmaceutical product class.